Welcome to our dedicated page for Healthcare Triangle SEC filings (Ticker: HCTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Healthcare Triangle, Inc. (HCTI) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. As an emerging growth company listed on The Nasdaq Stock Market LLC, Healthcare Triangle files a variety of reports that shed light on its healthcare IT and digital health operations, capital structure, and governance.
For investors analyzing HCTI, Form 10-K annual reports and Form 10-Q quarterly reports are central sources for understanding its healthcare information technology business, including cloud and data platforms (CloudEz™ and DataEz™), security and compliance services, data lifecycle management, interoperability work, and clinical and business performance optimization. These filings also describe risk factors, segment information, and accounting policies relevant to its software, managed services, and platform offerings.
Healthcare Triangle’s Form 8-K current reports are particularly important given the company’s active financing and acquisition strategy. Recent 8-Ks disclose:
- Material definitive agreements for senior unsecured convertible promissory notes under a Securities Purchase Agreement.
- Warrant inducement agreements and related new warrant issuances, including changes to exercise prices and registration commitments.
- Reverse stock split actions intended to address Nasdaq bid price requirements.
- Asset transfer and acquisition-related amendments involving Niyama Healthcare, Inc. and Ezovion Solutions Private Limited.
- Nasdaq compliance communications regarding listing rules and shareholder approval requirements.
Proxy statements on Schedule 14A detail proposals for electing directors, ratifying auditors, and obtaining shareholder approval for future securities issuances under Nasdaq Listing Rule 5635(d). These documents also explain voting rights, meeting logistics, and aspects of the company’s governance framework.
On this page, Stock Titan surfaces real-time updates from EDGAR and applies AI-powered summaries to key filings. Users can quickly see the main terms of financing agreements, the structure of warrant and note offerings, and the implications of reverse stock splits or listing determinations. Where applicable, insider ownership and voting power information disclosed in proxy materials can be reviewed alongside other filings, while Form 4 insider trading reports, when available, provide additional context on management and major holder transactions.
By combining raw SEC documents with AI-generated explanations, this filings hub helps investors, analysts, and researchers navigate Healthcare Triangle’s regulatory history and understand how its capital markets activity, acquisitions, and governance decisions support its healthcare IT and AI-driven digital health strategy.
Healthcare Triangle, Inc. amends its at-the-market program to increase the amount available for sale to $39,000,000 of common stock under the Sales Agreement with Spartan Capital Securities, LLC. This supplement notes $6,522,300.16 of shares were previously sold under the ATM Agreement and that sales may be made on Nasdaq or otherwise in at-the-market transactions.
The Sales Agent will sell on a commercially reasonable efforts basis and is not required to sell any specific number or dollar amount. The last reported sale price on Nasdaq on March 30, 2026 was $2.71 per share.
Healthcare Triangle, Inc. has authorized a new share repurchase program allowing the company to buy back up to $2,000,000 of its outstanding common stock. The Board approved the 2026 Share Repurchase Plan on March 9, 2026, and it became effective immediately.
The company may repurchase shares over time through open market purchases, privately negotiated transactions, or other methods in line with securities laws, including Rule 10b-18 and potential Rule 10b5-1 trading plans. Management will decide the timing and volume of any repurchases based on market conditions, the stock price, liquidity needs, legal requirements, and other factors.
The program does not require the company to repurchase any specific number of shares and can be suspended, modified, or discontinued at any time. Any shares bought back may be held as treasury stock or retired. Management describes the plan as part of a prudent capital allocation approach and a sign of confidence in the company’s long-term strategy.
Healthcare Triangle, Inc. reports via a Schedule 13G/A that Orca Capital beneficially owns 2,033 shares of common stock, equal to 0.2% of the class.
Ownership percentages are calculated based on 1,155,370 shares outstanding immediately after the issuer's registered offering as stated in the prospectus supplement filed pursuant to Rule 424(b)(5) on February 27, 2026.
Healthcare Triangle, Inc. Schedule 13G shows Orca Capital beneficially owns 86,058 shares of Common Stock, representing 7.4% of the class as reported immediately after the issuer's registered offering and tied to an aggregate outstanding count of 1,155,370 shares described in the prospectus supplement. The filing lists sole voting and dispositive power over 86,058 shares and is signed by Thomas Konig on 03/02/2026.
Healthcare Triangle, Inc. entered into a registered direct offering for 681,553 shares of common stock (or pre-funded warrants in lieu thereof) at $5.81 per share, for aggregate gross proceeds of approximately $3.95 million before fees and expenses.
The deal includes 421,553 common shares and 260,000 pre-funded warrants, which are immediately exercisable at $0.00001 per share and subject to beneficial ownership caps of 4.99% or 9.99%. The company plans to use the net proceeds for working capital and general corporate purposes.
D. Boral Capital LLC acted as sole placement agent and received a cash fee equal to 7% of the aggregate gross proceeds plus expense reimbursement. The securities were issued off an effective Form S-3 shelf registration statement and a prospectus supplement dated February 26, 2026.
Healthcare Triangle, Inc. is offering 421,553 shares of common stock at a public offering price of $5.81 per share and is also offering up to 260,000 Pre-Funded Warrants to certain institutional investors to avoid post-closing ownership above 4.99% (or at purchaser election 9.99%).
The prospectus supplement shows 733,817 shares of Common Stock outstanding before this offering and, assuming full exercise of the Pre-Funded Warrants, 1,415,370 shares outstanding after this offering. Net proceeds are estimated at $3,682,635 before expenses. The offering is being placed by D. Boral Capital LLC and the securities are expected to be issued in a single closing.
Healthcare Triangle, Inc. enacted a 1‑for‑60 reverse stock split of its common stock effective at 12:01 a.m. Eastern Time on February 10, 2026. Every sixty issued and outstanding shares were combined into one share, leaving the number of authorized shares unchanged.
The split reduced issued and outstanding common shares from 45,417,091 to 756,984, with no fractional shares issued; any fractional position was rounded up to the next whole share. Proportional adjustments were made to outstanding warrants, stock options, convertible securities, and equity plan reserves.
The move is part of the company’s plan to regain compliance with Nasdaq’s $1.00 minimum bid price requirement. Healthcare Triangle’s common stock continues to trade on the Nasdaq Capital Market under the symbol HCTI and now carries a new CUSIP number, 42227W 405.
Healthcare Triangle, Inc. reported the results of its 2026 virtual Special Stockholders Meeting held on February 2, 2026. Stockholders voted on two proposals, each requiring approval by a majority of shares present and entitled to vote.
The company had 10,758,725 shares of common stock and 20,000 shares of Series A Super Voting preferred stock outstanding as of the January 8, 2026 record date, for a total of 20,409,725 voting shares. At the meeting, about 66.35% of these voting shares were represented, satisfying quorum requirements.
The first proposal received 20,231,200 votes for, 175,869 against, and 1,656 abstentions. The second proposal received 20,199,168 votes for, 203,557 against, and 7,000 abstentions. Both proposals were approved under the stated voting standard.
Healthcare Triangle, Inc. completed the acquisition of Spanish companies Teyamé 360 S.L. and Datono Mediación S.L. through its subsidiary, with a total purchase price of up to $50.0 million.
Consideration includes staged cash payments, $12.0 million in restricted common stock, and $18.0 million in preferred stock that is convertible into common stock based on a VWAP-derived Base Price, subject to shareholder approval and a 19.99% issuance cap using pre-funded warrants if needed.
The agreement also provides for an earnout of up to $5.0 million in preferred stock for key managers tied to 2026 and 2027 revenue and EBITDA targets, as well as potential purchase-price adjustments if post-closing financial results fall short of assumptions. The securities issued were unregistered, relying on a private-offering exemption.
Healthcare Triangle, Inc. is asking stockholders to approve a reverse stock split of its common stock at a ratio between 1-for-2 and 1-for-100, with the exact ratio to be chosen later by the Board. The company explains that the main goal is to increase its share price to help maintain compliance with Nasdaq’s $1.00 minimum bid price requirement and reduce the risk of delisting.
The reverse split would reduce the 10,758,725 shares of common stock outstanding as of January 8, 2026 in proportion to the final ratio, without changing each holder’s overall ownership percentage apart from rounding up fractional shares to the next whole share. Authorized common shares would not be reduced, effectively increasing the number available for future issuance. A second proposal asks stockholders to allow adjournment of the special meeting, if needed, to solicit more proxies in support of the reverse split.